HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon

Stock News12-12 14:10

INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products Administration (NMPA) has approved its second-generation pan-TRK inhibitor, Zorletinib (ICP-723), for treating solid tumors in adults and adolescents aged 12 and above with NTRK fusion genes. Zorletinib has been included in NMPA's "Starlight Project," a pilot initiative to encourage pediatric oncology drug development. The company expects to soon submit a New Drug Application (NDA) for Zorletinib's use in pediatric patients aged 2 to 12. NTRK fusion genes are present in over 26 types of solid tumors, with an estimated 6,500 new cases annually in China. These patients often face short survival, rapid disease progression, and high disability rates. Due to low adoption of next-generation sequencing (NGS)—the gold standard for detection—diagnosis delays persist, leaving unmet clinical needs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178739772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 14:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178739772","market":"nz","top_or_hot":-1,"title":"HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon","media":"Stock News","content":"<p>INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products Administration (NMPA) has approved its second-generation pan-TRK inhibitor, Zorletinib (ICP-723), for treating solid tumors in adults and adolescents aged 12 and above with NTRK fusion genes. Zorletinib has been included in NMPA's \"Starlight Project,\" a pilot initiative to encourage pediatric oncology drug development. The company expects to soon submit a New Drug Application (NDA) for Zorletinib's use in pediatric patients aged 2 to 12. NTRK fusion genes are present in over 26 types of solid tumors, with an estimated 6,500 new cases annually in China. These patients often face short survival, rapid disease progression, and high disability rates. Due to low adoption of next-generation sequencing (NGS)—the gold standard for detection—diagnosis delays persist, leaving unmet clinical needs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 14:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products Administration (NMPA) has approved its second-generation pan-TRK inhibitor, Zorletinib (ICP-723), for treating solid tumors in adults and adolescents aged 12 and above with NTRK fusion genes. Zorletinib has been included in NMPA's \"Starlight Project,\" a pilot initiative to encourage pediatric oncology drug development. The company expects to soon submit a New Drug Application (NDA) for Zorletinib's use in pediatric patients aged 2 to 12. NTRK fusion genes are present in over 26 types of solid tumors, with an estimated 6,500 new cases annually in China. These patients often face short survival, rapid disease progression, and high disability rates. Due to low adoption of next-generation sequencing (NGS)—the gold standard for detection—diagnosis delays persist, leaving unmet clinical needs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1178739772","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178739772","pubTimestamp":1765519826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华"},"translate_title":"港股动向|诺诚健华(09969)涨超3%佐莱替尼儿科患者有望很快提交NDA","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"INNOCARE (09969) surged more than 3%, reaching HK$14 with a trading volume of HK$51.05 million by the time of reporting. On December 11, the company announced that China's National Medical Products Administration (NMPA) has approved its second-generation pan-TRK inhibitor, Zorletinib (ICP-723), for treating solid tumors in adults and adolescents aged 12 and above with NTRK fusion genes. Zorletinib has been included in NMPA's \"Starlight Project,\" a pilot initiative to encourage pediatric oncology drug development. The company expects to soon submit a New Drug Application (NDA) for Zorletinib's use in pediatric patients aged 2 to 12. NTRK fusion genes are present in over 26 types of solid tumors, with an estimated 6,500 new cases annually in China. These patients often face short survival, rapid disease progression, and high disability rates. Due to low adoption of next-generation sequencing (NGS)—the gold standard for detection—diagnosis delays persist, leaving unmet clinical needs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178739772","isCrawlerRequest":true}